Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Medtronic
Johnson and Johnson
McKinsey
Daiichi Sankyo
Boehringer Ingelheim
Federal Trade Commission
US Department of Justice
Chinese Patent Office
Novartis

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,642,258

« Back to Dashboard

Which drugs does patent 7,642,258 protect, and when does it expire?

Patent 7,642,258 protects COMBIGAN and is included in one NDA.

This patent has twenty-two patent family members in nineteen countries.
Summary for Patent: 7,642,258
Title:Combination of brimonidine and timolol for topical ophthalmic use
Abstract:Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.
Inventor(s): Chang; Chin-Ming (Tustin, CA), Beck; Gary J. (Fullerton, CA), Pratt; Cynthia C. (Mission Viejo, CA), Batoosingh; Amy L. (Mission Viejo, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:11/844,476
Patent Claim Types:
see list of patent claims
Composition; Use; Dosage form;

Drugs Protected by US Patent 7,642,258

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan COMBIGAN brimonidine tartrate; timolol maleate SOLUTION/DROPS;OPHTHALMIC 021398-001 Oct 30, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,642,258

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,030,149 Combination of brimonidine timolol for topical ophthalmic use ➤ Subscribe
9,474,751 Combination of brimonidine and timolol for topical ophthalmic use ➤ Subscribe
8,354,409 Combination of brimonidine and timolol for topical ophthalmic use ➤ Subscribe
8,748,425 Combination of brimonidine and timolol for topical ophthalmic use ➤ Subscribe
7,320,976 Combination of brimonidine and timolol for topical ophthalmic use ➤ Subscribe
7,323,463 Combination of brimonidine and timolol for topical ophthalmic use ➤ Subscribe
8,133,890 Combination of brimonidine and timolol for topical ophthalmic use ➤ Subscribe
9,770,453 Combination of brimonidine and timolol for topical ophthalmic use ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,642,258

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand 528945 ➤ Subscribe
Norway 20044450 ➤ Subscribe
Norway 326579 ➤ Subscribe
Mexico PA03008401 ➤ Subscribe
South Korea 100723189 ➤ Subscribe
South Korea 20040100844 ➤ Subscribe
Japan 2005523316 ➤ Subscribe
Hong Kong 1067549 ➤ Subscribe
Spain 2399045 ➤ Subscribe
European Patent Office 2241319 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Merck
Cantor Fitzgerald
QuintilesIMS
Federal Trade Commission
Covington
Fuji
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot